Passage Bio, Inc. (PASG)

1.2300 +0.0900 (+7.89%) 收市：04:00PM EDT

Passage Bio, Inc.

One Commerce Square
39th Floor 2005 Market Street
Philadelphia, PA 19103
United States
267 866 0311
https://www.passagebio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 58

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. William Chou M.D.	President, CEO & Director	945.73k	無	1974
Mr. Edgar B. Cale Esq., J.D.	General Counsel & Company Secretary	804.69k	無	1964
Dr. Mark Forman M.D., Ph.D.	Chief Medical Officer	866.31k	無	1964
Dr. James M. Wilson M.D., Ph.D.	Co-Founder & Chief Scientific Advisor	無	無	1955
Ms. Kathleen Borthwick	Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer	無	無	1977
Mr. Stuart M. Henderson	Senior Vice President of Corporate Development & Investor Relations	無	無	無
Eden Fucci	Senior Vice President of Technical Operations	無	無	無
Dr. Sue Browne Ph.D.	Senior Vice President of Research & Development	無	無	無
Dr. Karl Whitney Ph.D.	Senior Vice President of Global Regulatory Affairs	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

公司管治

截至 2024年4月1日 止，Passage Bio, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：2；董事會：7；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。